Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

517.90INR
23 May 2018
Change (% chg)

Rs6.05 (+1.18%)
Prev Close
Rs511.85
Open
Rs517.00
Day's High
Rs524.00
Day's Low
Rs512.00
Volume
926,071
Avg. Vol
844,017
52-wk High
Rs746.00
52-wk Low
Rs493.50

Select another date:

Mon, May 21 2018

BRIEF-Glenmark Pharmaceuticals Submitts NDA To U.S. FDA For Ryaltris

* GLENMARK PHARMACEUTICALS - SUBMITTED NDA TO U.S. FDA FOR LEADING RESPIRATORY PIPELINE CANDIDATE RYALTRIS Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharma Says Co Suspended Trial Conducted at Malpani Hospital After Alleged Irregularities

* CLARIFIES ON NEWS ITEM ABOUT CO GETTING NOTICE OVER MISCONDUCT IN CLINICAL TRIALS

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Clobetasol Propionate Topical Solution USP

* GETS ANDA APPROVAL FOR CLOBETASOL PROPIONATE TOPICAL SOLUTION USP

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Tacrolimus Ointment, 0.1 Pct

* SAYS CO GETS ANDA APPROVAL FOR TACROLIMUS OINTMENT, 0.1 PERCENT Source text - http://bit.ly/2HKxf5K Further company coverage:

BRIEF-Glenmark Pharmaceuticals, Helsinn Group Enter Into Agreement For Launch Of Akynzeo In India And Nepal

* SAYS CO, HELSINN GROUP ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR LAUNCH OF AKYNZEO IN INDIA AND NEPAL

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval From U.S. FDA For Clobetasol Propionate Spray, 0.05 Pct

* SAYS ‍CO GETS ANDA APPROVAL FROM U.S. FDA FOR CLOBETASOL PROPIONATE SPRAY, 0.05 PERCENT

BRIEF-Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals

* GLENMARK PHARMACEUTICALS - ‍ENTERED INTO EXCLUSIVE DEAL WITH SAM CHUN DANG PHARM

BRIEF-India's Glenmark Pharmaceuticals Dec-Qtr Consol Profit Falls 78 Pct

* DEC QUARTER CONSOL PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 4.77 BILLION RUPEES LAST YEAR

BRIEF-Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864

* GETS PERMISSION BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION FOR PHASE IIB DOSE RANGE FINDING STUDY FOR GRC 27864 Source text - http://bit.ly/2mEqR6R Further company coverage:

BRIEF-Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India

* LAUNCHES BIOSIMILAR OF ADALIMUMAB IN INDIA Source text for Eikon: Further company coverage:

Select another date: